Literature DB >> 14610662

2-Chloro-2'-deoxyadenosine: alteration of DNA:TATA element binding protein (TBP) interactions.

Theodore T Foley1, Patricia Hentosh, D Eric Walters.   

Abstract

2-Chloro-2'-deoxyadenosine (CldAdo, cladribine) is used therapeutically for hairy cell and other leukemias. The nucleoside is converted in leukemia cells to the 2-Cl-analog of dATP and incorporated into DNA, where it may alter binding of transcription factors to gene regulatory AT-rich sequences. Here we model the effects of CldATP incorporation into the adenovirus major late promoter TATA element recognized by TATA binding protein (TBP). The modeling results are consistent with experimental studies of DNA:TBP binding and indicate which positions in the canonical TATA sequence are most severely affected by CldATP incorporation.FIGURE Structure of the DNA:TBP complex. The protein is shown as a ribbon structure, and the DNA as a stick model

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610662     DOI: 10.1007/s00894-003-0163-8

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  14 in total

1.  Analysis of 2-chloro-2'-deoxyadenosine incorporation into cellular DNA by quantitative polymerase chain reaction.

Authors:  S H Yuh; M Tibudan; P Hentosh
Journal:  Anal Biochem       Date:  1998-08-15       Impact factor: 3.365

2.  Yeast and human TATA-binding proteins have nearly identical DNA sequence requirements for transcription in vitro.

Authors:  C R Wobbe; K Struhl
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

3.  Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.

Authors:  K Janiec; A Wajgt; Z Kondera-Anasz
Journal:  Med Sci Monit       Date:  2001 Jan-Feb

4.  Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase.

Authors:  W B Parker; A R Bapat; J X Shen; A J Townsend; Y C Cheng
Journal:  Mol Pharmacol       Date:  1988-10       Impact factor: 4.436

Review 5.  Cladribine in the treatment of chronic lymphocytic leukemia.

Authors:  T Robak
Journal:  Leuk Lymphoma       Date:  2001-02

6.  Crystal structure of a human TATA box-binding protein/TATA element complex.

Authors:  D B Nikolov; H Chen; E D Halay; A Hoffman; R G Roeder; S K Burley
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

7.  Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo.

Authors:  D A Carson; D B Wasson; J Kaye; B Ullman; D W Martin; R K Robins; J A Montgomery
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

Review 8.  Treatment of hairy-cell leukemia: current views.

Authors:  M S Tallman; L C Peterson; D Hakimian; S Gillis; A Polliack
Journal:  Semin Hematol       Date:  1999-04       Impact factor: 3.851

9.  Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.

Authors:  D A Carson; D B Wasson; R Taetle; A Yu
Journal:  Blood       Date:  1983-10       Impact factor: 22.113

10.  Incorporation of 2-halogeno-2'-deoxyadenosine 5-triphosphates into DNA during replication by human polymerases alpha and beta.

Authors:  P Hentosh; R Koob; R L Blakley
Journal:  J Biol Chem       Date:  1990-03-05       Impact factor: 5.157

View more
  2 in total

Review 1.  Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations.

Authors:  Eilhard Mix; Hans Meyer-Rienecker; Uwe K Zettl
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

Review 2.  Animal models of multiple sclerosis--potentials and limitations.

Authors:  Eilhard Mix; Hans Meyer-Rienecker; Hans-Peter Hartung; Uwe K Zettl
Journal:  Prog Neurobiol       Date:  2010-06-15       Impact factor: 11.685

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.